CADTH Canadian Drug Expert Committee recommendation: Ranolazine (Corzyna -- KYE pharmaceuticals Inc.) indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
May 2021, 2021
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers |
---|---|
Physical Description: | 1 PDF file (7 pages) |